A detailed history of Daiwa Securities Group Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 469 shares of HALO stock, worth $22,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares
469
Previous 469 -0.0%
Holding current value
$22,296
Previous $25,000 8.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$33.68 - $41.95 $2,391 - $2,978
-71 Reduced 13.15%
469 $19,000
Q4 2023

Jan 31, 2024

BUY
$33.32 - $42.1 $2,199 - $2,778
66 Added 13.92%
540 $20,000
Q2 2023

Jul 31, 2023

SELL
$30.28 - $38.74 $2,119 - $2,711
-70 Reduced 12.87%
474 $17,000
Q4 2022

Feb 06, 2023

BUY
$40.06 - $59.44 $1,201 - $1,783
30 Added 5.84%
544 $31,000
Q2 2022

Aug 09, 2022

BUY
$37.35 - $48.3 $3,847 - $4,974
103 Added 25.06%
514 $23,000
Q4 2021

Feb 03, 2022

SELL
$31.82 - $40.75 $2,418 - $3,097
-76 Reduced 15.61%
411 $17,000
Q3 2021

Nov 05, 2021

BUY
$38.47 - $46.42 $8,424 - $10,165
219 Added 81.72%
487 $20,000
Q1 2021

May 03, 2021

BUY
$39.51 - $51.45 $553 - $720
14 Added 5.51%
268 $11,000
Q4 2020

Feb 04, 2021

SELL
$25.81 - $43.62 $13,292 - $22,464
-515 Reduced 66.97%
254 $11,000
Q1 2020

May 14, 2020

SELL
$13.9 - $21.83 $806 - $1,266
-58 Reduced 7.01%
769 $14,000
Q4 2019

Jan 31, 2020

SELL
$14.93 - $19.53 $1,418 - $1,855
-95 Reduced 10.3%
827 $15,000
Q1 2019

Apr 26, 2019

BUY
$13.94 - $17.58 $1,881 - $2,373
135 Added 17.15%
922 $15,000
Q1 2018

May 02, 2018

BUY
$17.06 - $21.2 $13,426 - $16,684
787 New
787 $15,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.